Goldman Sachs Group Inc Arcturus Therapeutics Holdings Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 620,257 shares of ARCT stock, worth $9.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

620,257

Previous 509,712 21.69%

Holding current value

$9.24 Million

Previous $5.4 Million 49.51%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$8.91 - $14.41 $984,955 - $1.59 Million	110,545 Added 21.69%	620,257 $8.07 Million
Q1 2025 May 09, 2025	BUY	$10.59 - $20.83 $451,515 - $888,107	42,636 Added 9.13%	509,712 $5.4 Million
Q4 2024 Feb 11, 2025	BUY	$14.82 - $25.48 $648,715 - $1.12 Million	43,773 Added 10.34%	467,076 $7.93 Million
Q3 2024 Nov 14, 2024	SELL	$18.08 - $25.38 $402,063 - $564,400	-22,238 Reduced 4.99%	423,303 $9.82 Million
Q2 2024 Aug 13, 2024	BUY	$24.35 - $44.39 $2 Million - $3.65 Million	82,171 Added 22.61%	445,541 $10.8 Million
Q1 2024 May 15, 2024	SELL	$31.23 - $42.99 $1.6 Million - $2.2 Million	-51,271 Reduced 12.37%	363,370 $12.3 Million
Q4 2023 Feb 13, 2024	BUY	$17.71 - $32.97 $1.22 Million - $2.28 Million	69,156 Added 20.02%	414,641 $13.1 Million
Q3 2023 May 14, 2024	SELL	$25.44 - $37.35 $1.76 Million - $2.58 Million	-69,156 Reduced 16.68%	345,485 $8.83 Million
Q3 2023 Nov 14, 2023	SELL	$25.44 - $37.35 $820,211 - $1.2 Million	-32,241 Reduced 8.54%	345,485 $8.83 Million
Q2 2023 May 14, 2024	BUY	$23.94 - $32.36 $1.49 Million - $2.02 Million	62,324 Added 19.76%	377,726 $10.8 Million
Q2 2023 Aug 14, 2023	BUY	$23.94 - $32.36 $1.49 Million - $2.02 Million	62,324 Added 19.76%	377,726 $10.8 Million
Q1 2023 May 14, 2024	BUY	$14.72 - $23.97 $101,479 - $165,249	6,894 Added 2.23%	315,402 $7.56 Million
Q1 2023 May 11, 2023	BUY	$14.72 - $23.97 $101,479 - $165,249	6,894 Added 2.23%	315,402 $7.56 Million
Q4 2022 May 14, 2024	SELL	$14.14 - $23.06 $272,718 - $444,758	-19,287 Reduced 5.88%	308,508 $5.23 Million
Q4 2022 Feb 13, 2023	SELL	$14.14 - $23.06 $272,718 - $444,758	-19,287 Reduced 5.88%	308,508 $5.23 Million
Q3 2022 May 14, 2024	SELL	$13.05 - $22.13 $555,173 - $941,454	-42,542 Reduced 11.49%	327,795 $4.86 Million
Q3 2022 Nov 10, 2022	SELL	$13.05 - $22.13 $555,173 - $941,454	-42,542 Reduced 11.49%	327,795 $4.86 Million
Q2 2022 May 14, 2024	SELL	$12.26 - $31.17 $543,167 - $1.38 Million	-44,304 Reduced 10.68%	370,337 $5.83 Million
Q2 2022 Aug 15, 2022	BUY	$12.26 - $31.17 $1.08 Million - $2.75 Million	88,347 Added 31.33%	370,337 $5.83 Million
Q1 2022 May 16, 2022	BUY	$17.64 - $39.57 $152,868 - $342,913	8,666 Added 3.17%	281,990 $7.6 Million
Q4 2021 Feb 14, 2022	BUY	$34.2 - $47.56 $4.52 Million - $6.29 Million	132,196 Added 93.67%	273,324 $10.1 Million
Q3 2021 Nov 10, 2021	BUY	$27.88 - $58.25 $3.93 Million - $8.22 Million	141,128 New	141,128 $6.74 Million

Others Institutions Holding ARCT

# of Institutions

169

Shares Held

25.9M

Call Options Held

289K

Put Options Held

109K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $396M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Arcturus Therapeutics Holdings Inc. Transaction History